NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM
BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing...